Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic vasculitic syndromes

P A Bacon1

  • 1Department of Rheumatology, University of Birmingham, Edgbaston, UK.

Current Opinion in Rheumatology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Necrotizing vasculitis understanding is limited, with viral links and antibody classifications complicating diagnosis. Cyclophosphamide shows early benefit but no long-term survival improvement in this complex inflammatory condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Arthritis and rheumatism·2012
Same author

The Use of Quantitative Thermography to Assess the Anti-inflammatory Dose Range for Fenclofenac.

Proceedings of the Royal Society of Medicine·2010
Same author

Intracellular calcium signalling patterns reflect the differentiation status of human T cells.

Clinical and experimental immunology·2008
Same author

Impaired endothelial function in systemic lupus erythematosus.

Lupus·2007
Same author

Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis.

Annals of the rheumatic diseases·2005
Same author

Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects.

Current opinion in rheumatology·2004
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Necrotizing vasculitis pathogenesis and clinical expression remain poorly understood.
  • Localized vasculitis can progress to systemic involvement over time.
  • Viral infections, such as hepatitis C, are implicated but their mechanisms are unclear.

Purpose of the Study:

  • To review current knowledge gaps in necrotizing vasculitis.
  • To discuss diagnostic challenges including antibody classification and age-related presentations.
  • To evaluate therapeutic outcomes for necrotizing vasculitis.

Main Methods:

  • Review of recent literature on necrotizing vasculitis.
  • Analysis of clinical presentations and diagnostic markers.
  • Evaluation of treatment efficacy from controlled studies.

Related Experiment Videos

Main Results:

  • Cyclophosphamide therapy demonstrated early benefits but no significant difference in 10-year survival rates.
  • Plasma exchange provided benefit only for dialysis-dependent patients with severe renal involvement.
  • Classification challenges persist due to antibody associations with disease activity and extent.

Conclusions:

  • Further research is needed to elucidate the etiopathogenesis of necrotizing vasculitis.
  • Diagnostic criteria and classification require refinement.
  • Therapeutic strategies need optimization based on disease severity and specific patient factors.